NO175602C - Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid - Google Patents

Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid

Info

Publication number
NO175602C
NO175602C NO862313A NO862313A NO175602C NO 175602 C NO175602 C NO 175602C NO 862313 A NO862313 A NO 862313A NO 862313 A NO862313 A NO 862313A NO 175602 C NO175602 C NO 175602C
Authority
NO
Norway
Prior art keywords
preparation
interferon polypeptide
hybrid interferon
interferons
novel hybrid
Prior art date
Application number
NO862313A
Other languages
English (en)
Norwegian (no)
Other versions
NO862313D0 (no
NO862313L (no
NO175602B (no
Inventor
Francois Meyer
Albert Hinnen
Andreas Meister
Markus Gerhard Grutter
Sefik Alkan
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO862313D0 publication Critical patent/NO862313D0/no
Publication of NO862313L publication Critical patent/NO862313L/no
Publication of NO175602B publication Critical patent/NO175602B/no
Publication of NO175602C publication Critical patent/NO175602C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO862313A 1985-06-11 1986-06-10 Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid NO175602C (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon

Publications (4)

Publication Number Publication Date
NO862313D0 NO862313D0 (no) 1986-06-10
NO862313L NO862313L (no) 1986-12-12
NO175602B NO175602B (no) 1994-07-25
NO175602C true NO175602C (no) 1994-11-02

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
NO862313A NO175602C (no) 1985-06-11 1986-06-10 Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid

Country Status (20)

Country Link
US (2) US4885166A (de)
EP (1) EP0205404B1 (de)
JP (2) JPH0655759B2 (de)
KR (1) KR920002267B1 (de)
AT (1) ATE78262T1 (de)
AU (1) AU598196B2 (de)
CA (1) CA1285507C (de)
CY (1) CY1842A (de)
DE (1) DE3685996T2 (de)
DK (1) DK168794B1 (de)
FI (1) FI90983C (de)
GR (1) GR861497B (de)
HK (1) HK99895A (de)
HU (1) HU203255B (de)
IE (1) IE57865B1 (de)
IL (1) IL79085A (de)
NO (1) NO175602C (de)
NZ (1) NZ216485A (de)
PT (1) PT82736B (de)
SG (1) SG25195G (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (de) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
DE69129697T3 (de) * 1990-08-29 2004-01-29 Inst Genetics Llc Aus mehreren domänen bestehende hämatopoese-stimulatoren
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DK0548012T3 (da) * 1991-12-16 1998-04-14 Ciba Geigy Ag Endoplasmatisk reticulum-placeret rekombinant dibasisk endoprotease samt dens anvendelse
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0584343B1 (de) * 1992-03-10 1999-01-20 La Jolla Cancer Research Foundation Rekombinierte alkalische phosphatase aus kälberdarm
TW218846B (de) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (de) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
EP0801682B1 (de) 1995-02-09 2001-10-24 Novartis AG Verfahren zur produktion von proteinen
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
EP1121156B1 (de) 1998-10-16 2006-02-22 Biogen Idec MA Inc. Polymerkonjugate von interferon-beta-1a und deren verwendungen
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
MXPA03003933A (es) * 2000-11-03 2003-08-19 Biomedicines Inc Metodo para dosimetria de farmaco de duracion corta y duracion prolongada.
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
KR20040053291A (ko) * 2001-11-09 2004-06-23 바이오메디신즈 인코포레이티드 오메가 인터페론을 이용한 질환 치료 방법
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2504267A1 (en) * 2002-11-18 2004-06-03 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
MXPA06013412A (es) * 2004-05-19 2007-01-23 Maxygen Inc Polipeptidos de interferon-alfa y conjugados.
AU2005260664A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7619067B2 (en) 2005-05-18 2009-11-17 Maxygen, Inc. Evolved interferon-alpha polypeptides
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
PT2041259E (pt) 2006-07-14 2016-02-15 Dpx Holdings Bv Processo melhorado para a cultura de células
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20100143372A1 (en) 2006-12-06 2010-06-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
CN103965347B (zh) * 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
AU2008247398B2 (en) 2007-05-03 2013-10-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
US20110008365A1 (en) 2007-11-05 2011-01-13 Anthony Coyle Methods of treating scleroderma
KR20110005783A (ko) 2008-02-08 2011-01-19 메디뮨 엘엘씨 질환 마커 및 그의 용도
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
ME02599B (me) 2009-09-03 2017-06-20 Medimmune Llc Dijagnostičko sredstvo interferon tipa 1
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
BR112013023609A8 (pt) 2011-03-15 2018-04-03 Biogen Idec Inc Método para a redução de sintomas parecidos com a gripe associado com a administração intramuscular de interferon ao usar um regime de dosagem escalonado de titulação rápida
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
JP7522749B2 (ja) 2019-02-15 2024-07-25 アストラゼネカ・アクチエボラーグ Ｉ型インターフェロン媒介性障害
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK170236B1 (da) * 1980-01-08 1995-07-10 Biogen Inc Rekombinante DNA-molekyler, fremgangsmåde til fremstilling af et polypeptid af IFN-alfa typen og fremgangsmåde til udvælgelse af DNA-sekvenser, der koder for polypeptider af IFN-alfa typen
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
EP0098876A1 (de) * 1982-01-19 1984-01-25 Cetus Corporation Hybrid-interferone verschiedener klassen
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
EP0173935A1 (de) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid-Lymphoblastoid-Leukozyten-Humaninterferone

Also Published As

Publication number Publication date
DK168794B1 (da) 1994-06-13
FI862461L (fi) 1986-12-12
NO862313D0 (no) 1986-06-10
NO862313L (no) 1986-12-12
SG25195G (en) 1995-08-18
CA1285507C (en) 1991-07-02
KR920002267B1 (ko) 1992-03-20
JPH0655759B2 (ja) 1994-07-27
AU598196B2 (en) 1990-06-21
IL79085A (en) 1992-03-29
IE861542L (en) 1986-12-11
CY1842A (en) 1996-03-08
EP0205404B1 (de) 1992-07-15
GR861497B (en) 1986-10-10
US5071761A (en) 1991-12-10
US4885166A (en) 1989-12-05
DE3685996D1 (de) 1992-08-20
AU5849986A (en) 1986-12-18
HUT41846A (en) 1987-05-28
EP0205404A2 (de) 1986-12-17
PT82736B (pt) 1988-12-15
JPS626000A (ja) 1987-01-12
FI90983C (fi) 1994-04-25
ATE78262T1 (de) 1992-08-15
KR870000427A (ko) 1987-02-18
EP0205404A3 (en) 1987-10-21
IE57865B1 (en) 1993-05-05
NZ216485A (en) 1991-06-25
HK99895A (en) 1995-06-30
PT82736A (en) 1986-07-01
DE3685996T2 (de) 1993-01-14
FI862461A0 (fi) 1986-06-09
NO175602B (no) 1994-07-25
DK272986A (da) 1986-12-12
DK272986D0 (da) 1986-06-10
HU203255B (en) 1991-06-28
JPH05308973A (ja) 1993-11-22
FI90983B (fi) 1994-01-14
IL79085A0 (en) 1986-09-30
JPH0736757B2 (ja) 1995-04-26

Similar Documents

Publication Publication Date Title
NO175602C (no) Fremgangsmåte for fremstilling av et hybridinterferon-polypeptid
ES2119735T3 (es) Ifn-beta2/il-6 humano, su purificacion y sus utilizaciones.
FI874287A7 (fi) Uudet lymfokiinipeptidit.
ES8601237A1 (es) Procedimiento para preparar dnas y dnas recombinantes
NZ212937A (en) Omega interferons: production by recombinant dna processes; pharmaceutical compositions
EP0315637A4 (de) Polypeptide zur verwendung bei der diagnose von mycoplasmainfektionen bei schweinen, sowie rekombinant-dns-verfahren zur herstellung derselben.
FI873593L (fi) Nya applikationsformer foer -interferon.
DE3169559D1 (en) Lymphoblastoid cell lines capable of continuously and spontaneously producing interferon, process for preparing the same, and process for the human interferon production by the same
AU1702488A (en) Polypeptides useful in diagnosis of coccidia infection and recombinant-dna methods for manufacturing same
FR2527448B1 (fr) Procede de production d'interferon
NO166727C (no) Fremgangsmaate for fremstilling av rekombinant alfa-interferon
ATE50597T1 (de) Alpha-interferon gx-1.
FI874273A0 (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
GB2168355B (en) Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
IL92316A0 (en) Recombinant interleukin-2 hybrid proteins,their production and pharmaceutical compositions containing them
ES2052562T3 (es) Peptido antineoplasico inducido por la interleucina-2.
ATE102997T1 (de) Thymosin und tnf-kodierende dna.

Legal Events

Date Code Title Description
MK1K Patent expired